These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 16262618)

  • 21. Influence of white versus gray mineral trioxide aggregate on inflammatory cells.
    Vosoughhosseini S; Lotfi M; Shahi S; Baloo H; Mesgariabbasi M; Saghiri MA; Zand V; Rahimi S; Ranjkesh B
    J Endod; 2008 Jun; 34(6):715-7. PubMed ID: 18498897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro cytotoxicity and in vivo biocompatibility of contemporary resin-modified glass-ionomer cements.
    Souza PP; Aranha AM; Hebling J; Giro EM; Costa CA
    Dent Mater; 2006 Sep; 22(9):838-44. PubMed ID: 16387357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of bisphosphonates on osteoblasts in vitro.
    Naidu A; Dechow PC; Spears R; Wright JM; Kessler HP; Opperman LA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul; 106(1):5-13. PubMed ID: 18504149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial.
    Graziani F; Rosini S; Cei S; La Ferla F; Gabriele M
    J Craniofac Surg; 2008 Jul; 19(4):1061-6. PubMed ID: 18650733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells.
    Panzavolta S; Torricelli P; Bracci B; Fini M; Bigi A
    J Inorg Biochem; 2009 Jan; 103(1):101-6. PubMed ID: 18977031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of white mineral trioxide aggregate mixed with disodium hydrogen phosphate on inflammatory cells.
    Lotfi M; Vosoughhosseini S; Saghiri MA; Mesgariabbasi M; Ranjkesh B
    J Endod; 2009 May; 35(5):703-5. PubMed ID: 19410087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of an estrogen-deficient state and alendronate therapy on bone loss resulting from experimental periapical lesions in rats.
    Xiong H; Peng B; Wei L; Zhang X; Wang L
    J Endod; 2007 Nov; 33(11):1304-8. PubMed ID: 17963952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug injury in the upper gastrointestinal tract: effects of alendronate.
    Khapra AP; Rose S
    Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of alendronate on endosseous implant integration: an in vivo study in rabbits.
    Chacon GE; Stine EA; Larsen PE; Beck FM; McGlumphy EA
    J Oral Maxillofac Surg; 2006 Jul; 64(7):1005-9. PubMed ID: 16781331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo comparison of the biocompatibility of two root canal sealers implanted into the subcutaneous connective tissue of rats.
    Zafalon EJ; Versiani MA; de Souza CJ; Moura CC; Dechichi P
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):e88-94. PubMed ID: 17320427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
    Singh US; Shankar R; Kumar A; Trivedi R; Chattopadhyay N; Shakya N; Palne S; Gupta S; Hajela K
    Bioorg Med Chem; 2008 Sep; 16(18):8482-91. PubMed ID: 18752963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nodular scleritis following alendronate therapy.
    Tabbara KF
    Ocul Immunol Inflamm; 2008; 16(3):99-101. PubMed ID: 18569796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation.
    Heino TJ; Chagin AS; Takigawa M; Sävendahl L
    Bone; 2008 Apr; 42(4):702-9. PubMed ID: 18276203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)].
    Harper RP; Fung E
    J Oral Maxillofac Surg; 2007 Mar; 65(3):573-80. PubMed ID: 17307613
    [No Abstract]   [Full Text] [Related]  

  • 37. [Persistent polyarticular synovitis after treatment with alendronate].
    Frederiksen L; Junker P; Brixen KT
    Ugeskr Laeger; 2007 Apr; 169(17):1583-4. PubMed ID: 17484832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the tissue reaction to fast endodontic cement (CER) and Angelus MTA.
    Gomes-Filho JE; Rodrigues G; Watanabe S; Estrada Bernabé PF; Lodi CS; Gomes AC; Faria MD; Domingos Dos Santos A; Silos Moraes JC
    J Endod; 2009 Oct; 35(10):1377-80. PubMed ID: 19801233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells.
    Hashimoto K; Morishige K; Sawada K; Tahara M; Shimizu S; Ogata S; Sakata M; Tasaka K; Kimura T
    Biochem Biophys Res Commun; 2007 Mar; 354(2):478-84. PubMed ID: 17240356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of alendronate and risk of incident atrial fibrillation in women.
    Heckbert SR; Li G; Cummings SR; Smith NL; Psaty BM
    Arch Intern Med; 2008 Apr; 168(8):826-31. PubMed ID: 18443257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.